样式: 排序: IF: - GO 导出 标记为已读
-
Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-03-15 Fahan Ma, Yan Li, Chan Xiang, Bing Wang, Jie Lv, Jinzhi Wei, Zhaoyu Qin, Yan Pu, Kai Li, Haohua Teng, Subei Tan, Jinwen Feng, Zhanxian Shang, Yunzhi Wang, Sha Tian, Changsheng Du, Yuchen Han, Chen Ding
Immunotherapy is the first-line therapy for esophageal squamous cell carcinoma (ESCC), yet many patients do not respond due to drug resistance and the lack of reliable predictive markers. We collected 73 ESCC patients (including discovery cohort and validation cohort) without immune thrombocytopenia and undergoing anti-PD1 immunotherapy. Proteomic and phosphoproteomic analysis of 73 ESCC treatment-naive
-
Optical nanomaterial-based detection of biomarkers in liquid biopsy J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-03-14 Young Jun Kim, Won-Yeop Rho, Seung-min Park, Bong-Hyun Jun
Liquid biopsy, which is a minimally invasive procedure as an alternative to tissue biopsy, has been introduced as a new diagnostic/prognostic measure. By screening disease-related markers from the blood or other biofluids, it promises early diagnosis, timely prognostication, and effective treatment of the diseases. However, there will be a long way until its realization due to its conceptual and practical
-
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-02-24 Zeda Zhao, Juliang Qin, Ying Qian, Chenshen Huang, Xiaohong Liu, Ning Wang, Liqin Li, Yuqing Chao, Binghe Tan, Na Zhang, Min Qian, Dali Li, Mingyao Liu, Bing Du
Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor cells (MDSCs) are pathologically activated and extremely immunosuppressive, which are closely associated with poor clinical outcomes of cancer patients. However, the correlation between MDSCs mediated
-
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-02-09 Astrid Van den Eynde, Laura Gehrcken, Tias Verhezen, Ho Wa Lau, Christophe Hermans, Hilde Lambrechts, Tal Flieswasser, Delphine Quatannens, Gils Roex, Karen Zwaenepoel, Elly Marcq, Philippe Joye, Edgar Cardenas De La Hoz, Christophe Deben, Alessia Gasparini, Pierre Montay-Gruel, Maxim Le Compte, Eva Lion, Filip Lardon, Steven Van Laere, Vasiliki Siozopoulou, Diana Campillo-Davo, Jorrit De Waele, Patrick
It remains challenging to obtain positive outcomes with chimeric antigen receptor (CAR)-engineered cell therapies in solid malignancies, like colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). A major obstacle is the lack of targetable surface antigens that are not shared by healthy tissues. CD70 emerges as interesting target, due to its stringent expression pattern in healthy tissue
-
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-02-01 Meilin Xue, Lei Dong, Honghai Zhang, Yangchan Li, Kangqiang Qiu, Zhicong Zhao, Min Gao, Li Han, Anthony K. N. Chan, Wei Li, Keith Leung, Kitty Wang, Sheela Pangeni Pokharel, Ying Qing, Wei Liu, Xueer Wang, Lili Ren, Hongjie Bi, Lu Yang, Chao Shen, Zhenhua Chen, Laleh Melstrom, Hongzhi Li, Nikolai Timchenko, Xiaolan Deng, Wendong Huang, Steven T. Rosen, Jingyan Tian, Lin Xu, Jiajie Diao, Chun-Wei Chen
While liver cancer stem cells (CSCs) play a crucial role in hepatocellular carcinoma (HCC) initiation, progression, recurrence, and treatment resistance, the mechanism underlying liver CSC self-renewal remains elusive. We aim to characterize the role of Methyltransferase 16 (METTL16), a recently identified RNA N6-methyladenosine (m6A) methyltransferase, in HCC development/maintenance, CSC stemness
-
Metabolic reprogramming in the tumor microenvironment of liver cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-01-31 Jian Lin, Dongning Rao, Mao Zhang, Qiang Gao
The liver is essential for metabolic homeostasis. The onset of liver cancer is often accompanied by dysregulated liver function, leading to metabolic rearrangements. Overwhelming evidence has illustrated that dysregulated cellular metabolism can, in turn, promote anabolic growth and tumor propagation in a hostile microenvironment. In addition to supporting continuous tumor growth and survival, disrupted
-
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-01-17 Hongying Zhang, Yongliang Liu, Jieya Liu, Jinzhu Chen, Jiao Wang, Hui Hua, Yangfu Jiang
Cancer is a complex disease resulting from abnormal cell growth that is induced by a number of genetic and environmental factors. The tumor microenvironment (TME), which involves extracellular matrix, cancer-associated fibroblasts (CAF), tumor-infiltrating immune cells and angiogenesis, plays a critical role in tumor progression. Cyclic adenosine monophosphate (cAMP) is a second messenger that has
-
Vaccines: a promising therapy for myelodysplastic syndrome J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-01-08 Kriti Gera, Anjali Chauhan, Paul Castillo, Maryam Rahman, Akash Mathavan, Akshay Mathavan, Elizabeth Oganda-Rivas, Leighton Elliott, John R. Wingard, Elias J. Sayour
Myelodysplastic neoplasms (MDS) define clonal hematopoietic malignancies characterized by heterogeneous mutational and clinical spectra typically seen in the elderly. Curative treatment entails allogeneic hematopoietic stem cell transplant, which is often not a feasible option due to older age and significant comorbidities. Immunotherapy has the cytotoxic capacity to elicit tumor-specific killing with
-
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-01-08 Lawrence W. Liu, Mei Wang, Nikhil Grandhi, Mark A. Schroeder, Theodore Thomas, Kristin Vargo, Feng Gao, Kristen M. Sanfilippo, Su-Hsin Chang
Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, it is unclear whether TCDD/AO exposure (AO exposure hereafter) increases the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to MM. We sought to evaluate the association
-
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-01-07 Claire Lacan, Jérôme Lambert, Edouard Forcade, Marie Robin, Patrice Chevallier, Sandrine Loron, Claude-Éric Bulabois, Corentin Orvain, Patrice Ceballos, Etienne Daguindau, Amandine Charbonnier, Yves Chalandon, Marc Bernard, Célestine Simand, Marie-Thérèse Rubio, Pascal Turlure, Johan Maertens, Anne Huynh, Michael Loschi, Jacques-Olivier Bay, Gaëlle Guillerm, Mustafa Alani, Cristina Castilla-Llorente
The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis remains controversial. Moreover, the value of adding anti-thymoglobulin (ATG) to PTCy is unknown. A total of 1344 adult patients received an unmanipulated haploidentical transplant
-
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors J. Hematol. Oncol. (IF 28.5) Pub Date : 2024-01-04 Qing Wei, Peijing Li, Teng Yang, Jiayu Zhu, Lu Sun, Ziwen Zhang, Lu Wang, Xuefei Tian, Jiahui Chen, Can Hu, Junli Xue, Letao Ma, Takaya Shimura, Jianmin Fang, Jieer Ying, Peng Guo, Xiangdong Cheng
Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of ADC combinations with a variety of anticancer drugs, encompassing chemotherapy, molecularly targeted agents, and immunotherapy, are being rigorously conducted in both preclinical studies and clinical trial settings. Nevertheless
-
Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-18 Le-Wei Zheng, Cui-Cui Liu, Ke-Da Yu
Liquid–liquid phase separation (LLPS) is a novel principle for interpreting precise spatiotemporal coordination in living cells through biomolecular condensate (BMC) formation via dynamic aggregation. LLPS changes individual molecules into membrane-free, droplet-like BMCs with specific functions, which coordinate various cellular activities. The formation and regulation of LLPS are closely associated
-
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-16 Julie M. Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K. Link, Melissa H. Cessna, Paul M. Barr, Brad S. Kahl, Matthew S. Mckinney, Nadia Khan, Ranjana H. Advani, Peter Martin, Andre H. Goy, Tycel J. Phillips, Amitkumar Mehta, Manali Kamdar, Michael Crump, Barbara Pro, Christopher R. Flowers, Caron A. Jacobson, Sonali M. Smith
Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of this disease. This study aims to investigate the clinical and pathological features of MCL in the immunochemotherapy era and improve the prognostic models for
-
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-16 Dairan Zhou, Zhenyu Gong, Dejun Wu, Chao Ma, Lijun Hou, Xiaomin Niu, Tao Xu
Brain metastases signify a deleterious milestone in the progression of several advanced cancers, predominantly originating from lung, breast and melanoma malignancies, with a median survival timeframe nearing six months. Existing therapeutic regimens yield suboptimal outcomes; however, burgeoning insights into the tumor microenvironment, particularly the immunosuppressive milieu engendered by tumor–brain
-
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-15 Won-Min Song, Abdulkadir Elmas, Richard Farias, Peng Xu, Xianxiao Zhou, Benjamin Hopkins, Kuan-lin Huang, Bin Zhang
Global proteomic data generated by advanced mass spectrometry (MS) technologies can help bridge the gap between genome/transcriptome and functions and hold great potential in elucidating unbiased functional models of pro-tumorigenic pathways. To this end, we collected the high-throughput, whole-genome MS data and conducted integrative proteomic network analyses of 687 cases across 7 cancer types including
-
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2 J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-14 Sara Pusceddu, Francesca Corti, Natalie Prinzi, Federico Nichetti, Silva Ljevar, Adele Busico, Tommaso Cascella, Rita Leporati, Simone Oldani, Chiara Carlotta Pircher, Jorgelina Coppa, Veronica Resi, Massimo Milione, Marco Maccauro, Rosalba Miceli, Elena Tamborini, Federica Perrone, Carlo Spreafico, Monica Niger, Federica Morano, Filippo Pietrantonio, Ettore Seregni, Luigi Mariani, Vincenzo Mazzaferro
In retrospective studies, metformin use has been associated with better clinical outcomes in diabetic patients with advanced, well-differentiated neuroendocrine tumors (WDNETs). However, prospective evidence of metformin safety and activity is lacking. Here, we conducted the first-in-human phase Ib MetNET2 trial to investigate the safety and antitumor activity of metformin in combination with the somatostatin
-
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-12 Alfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, Cristina Nieto-Jiménez, Lucía Paniagua-Herranz, Adrián Sanvicente, Emiliano Calvo, Pedro Pérez-Segura, Víctor Moreno, Francisco Moris, Alberto Ocana
Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA), a cytotoxic payload, and a chemical linker that binds both. To this regard, most efforts have been focused on target identification, antibody design and linker optimization
-
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-12-12 Anja Seckinger, Sara Majocchi, Valéry Moine, Lise Nouveau, Hoang Ngoc, Bruno Daubeuf, Ulla Ravn, Nicolas Pleche, Sebastien Calloud, Lucile Broyer, Laura Cons, Adeline Lesnier, Laurence Chatel, Anne Papaioannou, Susana Salgado-Pires, Sebastian Krämer, Ines Gockel, Florian Lordick, Krzysztof Masternak, Yves Poitevin, Giovanni Magistrelli, Pauline Malinge, Limin Shang, Sonja Kallendrusch, Klaus Strein
T-cell retargeting to eliminate CEACAM5-expressing cancer cells via CEACAM5xCD3 bispecific antibodies (BsAbs) showed limited clinical activity so far, mostly due to insufficient T-cell activation, dose-limiting toxicities, and formation of anti-drug antibodies (ADA). We present here the generation and preclinical development of NILK-2301, a BsAb composed of a common heavy chain and two different light
-
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-30 Jiatong Liu, Xiaoyue Han, Tingyue Zhang, Keyue Tian, Zhaoping Li, Feng Luo
Inflammation is a fundamental defensive response to harmful stimuli, but the overactivation of inflammatory responses is associated with most human diseases. Reactive oxygen species (ROS) are a class of chemicals that are generated after the incomplete reduction of molecular oxygen. At moderate levels, ROS function as critical signaling molecules in the modulation of various physiological functions
-
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-29 Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu
T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that confer tumor-mediated immunosuppression. Developing a novel nanobody-based trispecific T cell engager (Nb-TriTE) would be a potential strategy to improve therapeutic
-
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-27 Chaoyi Zhang, Jin Xu, Rong Tang, Jianhui Yang, Wei Wang, Xianjun Yu, Si Shi
Research into the potential benefits of artificial intelligence for comprehending the intricate biology of cancer has grown as a result of the widespread use of deep learning and machine learning in the healthcare sector and the availability of highly specialized cancer datasets. Here, we review new artificial intelligence approaches and how they are being used in oncology. We describe how artificial
-
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-22 Long Chen, Anqi Ren, Yuan Zhao, Hangyu Chen, Qifang Wu, Mengzhu Zheng, Zijian Zhang, Tongcun Zhang, Wu Zhong, Jian Lin, Haichuan Zhu
T-cell acute lymphoblastic leukemia (T-ALL) is a type of hematologic tumor with malignant proliferation of hematopoietic progenitor cells. However, traditional clinical treatment of T-ALL included chemotherapy and stem cell transplantation always lead to recurrence and poor prognosis, thus new therapeutic targets and drugs are urgently needed for T-ALL treatment. In this study, we showed that TET1
-
Genitourinary cancers updates: highlights from ASCO 2023 J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-21 Qian Qin, Hollie Sheffield, Sean M. Taasan, Andrew Z. Wang, Tian Zhang
Significant scientific advances in immunotherapy and targeted therapy approaches have improved clinical outcomes and increased treatment options for patients with genitourinary (GU) malignancies. We highlight the clinical trial developments released at the ASCO 2023 annual meeting, including PARP inhibitors for prostate cancer, antibody drug conjugates and fibroblast growth factor receptor inhibitors
-
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-09 Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma
Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performed a multicenter retrospective cohort study to evaluate the outcomes of patients with secondary CNS lymphoma (SCNSL) who received CAR-T. Eligibility required active
-
Correction: Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-04 Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang, Ming-Yuan Chen, Gang Ma, Ling Guo, Jian-Chuan Xia
Correction: Journal of Hematology & Oncology (2020) 13:2 https://doi.org/10.1186/s13045-019-0840-4 The original article [1] contains an erroneous bottom-right panel of Fig. 6F. The corrected sub-figure can be viewed ahead in this Correction article. Fig. 6 AGK stimulates the PI3K/AKT signalling pathway. a KEGG analysis was conducted to identify the pathways activated by AGK overexpression in RCC. b
-
Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-11-01 Zengyu Feng, Kexian Li, Kai Qin, Juyong Liang, Minmin Shi, Yang Ma, Shiwei Zhao, Huaiyu Liang, Dongni Han, Baiyong Shen, Chenghong Peng, Hao Chen, Lingxi Jiang
Retraction to: Journal of Hematology & Oncology (2022) 15:112 https://doi.org/10.1186/s13045-022-01338-9 The Editor-in-Chief has retracted this article because of significant concerns regarding a number of Figures presented in this work, which question the integrity of the data. The Editor-in-Chief therefore no longer has confidence in the integrity of the data in this article. Lingxi Jiang does not
-
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-10-25 Yannick Bulliard, Borje S. Andersson, Mehmet A. Baysal, Jason Damiano, Apostolia M. Tsimberidou
T cell differentiation is a highly regulated, multi-step process necessary for the progressive establishment of effector functions, immunological memory, and long-term control of pathogens. In response to strong stimulation, as seen in severe or chronic infections or cancer, T cells acquire a state of hypo-responsiveness known as exhaustion, limiting their effector function. Recent advances in autologous
-
CRISPR screening in hematology research: from bulk to single-cell level J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-10-24 Sarah Meyers, Sofie Demeyer, Jan Cools
The CRISPR genome editing technology has revolutionized the way gene function is studied. Genome editing can be achieved in single genes or for thousands of genes simultaneously in sensitive genetic screens. While conventional genetic screens are limited to bulk measurements of cell behavior, recent developments in single-cell technologies make it possible to combine CRISPR screening with single-cell
-
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-29 Arnon Nagler, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Lucia Lopez Corral, Stefania Bramanti, Simona Sica, Mi Kwon, Yener Koc, Jiri Pavlu, Alexander Kulagin, Alessandro Busca, Arancha Bermúdez Rodríguez, Péter Reményi, Christoph Schmid, Eolia Brissot, Jaime Sanz, Ali Bazarbachi, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Correction : Journal of Hematology & Oncology (2023) 16:58 https://doi.org/10.1186/s13045-023-01450-4 The original article [1] incorrectly presents Affiliation 7. The correct affiliation can be viewed ahead in this Correction article: 7Transplantation Unit Department of Oncology and Haematology, IRCCS Humanitas Research Hospital, Milan, Italy. Nagler A, et al. Non-T-depleted haploidentical transplantation
-
Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-29 Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yangqiu Li
Correction to: Cai et al. Journal of Hematology & Oncology (2023) 16:101 https://doi.org/10.1186/s13045-023-01499-1 The original article [1] contained an error mistakenly introduced by the production team whereby co-first authorship for the first three co-authors was omitted. This has since been restored accordingly. Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
-
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-14 Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke van den Berg, Marcel Nijland
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic
-
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-12 Hao-Ran Jin, Jin Wang, Zi-Jing Wang, Ming-Jia Xi, Bi-Han Xia, Kai Deng, Jin-Lin Yang
Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and survive in unfavorable environments that lack oxygen and nutrients, tumor cells undergo metabolic transformations to exploit various ways of acquiring lipid and increasing lipid oxidation. In addition, stromal cells and immune cells in the tumor microenvironment also undergo lipid metabolic
-
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-09 Changsong Qi, Tong Xie, Jun Zhou, Xicheng Wang, Jifang Gong, Xiaotian Zhang, Jian Li, Jiajia Yuan, Chang Liu, Lin Shen
Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT04581473 and NCT03874897). In case 1, with CLDN 18.2 expression of 2+, 70%, 250 × 106 cells were infused after lymphodepletion. Grade 1 cytokine release syndrome (CRS) occurred on d1 which was later
-
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-05 Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yangqiu Li
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies. Thus, an increasing number of immune checkpoint proteins (ICPs) have been screened
-
Recent advances in targeted strategies for triple-negative breast cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-28 Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple
-
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-25 Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla
Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors (BTKi). BTKi has shown excellent outcomes for patients with relapsed or refractory MCL and is now being studied in
-
Advances in single-cell RNA sequencing and its applications in cancer research J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-24 Dezhi Huang, Naya Ma, Xinlei Li, Yang Gou, Yishuo Duan, Bangdong Liu, Jing Xia, Xianlan Zhao, Xiaoqi Wang, Qiong Li, Jun Rao, Xi Zhang
Cancers are a group of heterogeneous diseases characterized by the acquisition of functional capabilities during the transition from a normal to a neoplastic state. Powerful experimental and computational tools can be applied to elucidate the mechanisms of occurrence, progression, metastasis, and drug resistance; however, challenges remain. Bulk RNA sequencing techniques only reflect the average gene
-
Challenges and new technologies in adoptive cell therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-18 Pengchao Zhang, Guizhong Zhang, Xiaochun Wan
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and chimeric antigen receptor (CAR)-T cell therapies, many novel strategies for cancer treatment have been developed. Owing to its promising outcomes, CAR-T cell therapy has revolutionized the field of ACTs, particularly for
-
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-17 Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel, Sabine Kayser, Konstanze Döhner, Michael Heuser, Felicitas Thol, Silke Kapp-Schwoerer, Jannik Labrenz, Dominic Edelmann, Melanie Märklin, Wichard Vogel, Wolfgang Bethge, Juliane S. Walz, Ludger Große-Hovest, Martin Steiner, Gundram Jung, Helmut R. Salih
About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, which is abundantly expressed on AML cells. This first-in-human, open-label, single-arm, multicenter trial included AML patients in CR with persisting or increasing MRD and evaluated safety/tolerability
-
Retraction Note: HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-15 Huajie Song, Dan Li, Xiaojing Wang, Erhu Fang, Feng Yang, Anpei Hu, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Kai Huang, Liduan Zheng, Qiangsong Tong
Retraction Note: Journal of Hematology & Oncology (2020) 13:24 https://doi.org/10.1186/s13045-020-00857-7 The Editor-in-Chief has retracted this article. After publication, concerns were raised about image reuse in the article. Specifically: The top-left panel of Fig. 2F was reproduced in two panels of Fig. 4H, and in Fig. S11E of the supplementary materials. There is overlap between the top-left panel
-
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-12 Mengke Niu, Ming Yi, Yuze Wu, Lijuan Lyu, Qing He, Rui Yang, Liang Zeng, Jian Shi, Jing Zhang, Pengfei Zhou, Tingting Zhang, Qi Mei, Qian Chu, Kongming Wu
Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not sufficient to restore normal immune response. Other negative regulators of antitumor immunity, like TGF-β and VEGFA, are also involved in immune escape of tumor cells and induce immunotherapy resistance
-
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-08 Matthieu Roulleaux-Dugage, Antoine Italiano
Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology
-
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-03 Juanjuan Zhao, Quan Ren, Xinyuan Liu, Xiangqian Guo, Yongping Song
Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for relapsed/refractory MM therapy in 2022, while elranatamab, linvoseltamab, F182112, talquetamab, and cevostamab are currently undergoing clinical trials. This study summarizes several latest reports on bsAbs for the treatment
-
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-03 Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D. Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K. Balasubramanian, Hussein Awada, Ramsha Ahmed, Minako Mori, Manja Meggendorfer, Torsten Haferlach, Valeria Visconte, Jaroslaw P. Maciejewski
TP53 mutations (TP53MT) occur in diverse genomic configurations. Particularly, biallelic inactivation is associated with poor overall survival in cancer. Lesions affecting only one allele might not be directly leukemogenic, questioning the presence of cryptic biallelic subclones in cases with dismal prognosis. We have collected clinical and molecular data of 7400 patients with myeloid neoplasms and
-
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-03 Xinyuan Liu, Juanjuan Zhao, Xiangqian Guo, Yongping Song
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20+ NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on
-
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-08-02 Ya-Nan Qi, Zhu Liu, Lian-Lian Hong, Pei Li, Zhi-Qiang Ling
RNA modification has recently become a significant process of gene regulation, and the methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification, methylating various types of RNAs, including mRNA, tRNA, microRNA, rRNA, and mitochondrial RNAs. METTL proteins consist of a unique seven-beta-strand domain, which binds to the methyl donor SAM to catalyze methyl transfer
-
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-31 Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound and prolonged cytopenias) represents the most common grade ≥ 3 toxicity and can predispose for severe infectious complications. Here, we examined
-
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-31 Dong-Jun Fu, Ting Wang
NEDDylation, a post-translational modification through three-step enzymatic cascades, plays crucial roles in the regulation of diverse biological processes. NEDD8-activating enzyme (NAE) as the only activation enzyme in the NEDDylation modification has become an attractive target to develop anticancer drugs. To date, numerous inhibitors or agonists targeting NAE have been developed. Among them, covalent
-
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-28 James F. Wu, Binod Dhakal
Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two approved BCMA-targeted CAR-T cell therapies, investigators globally are working to build off and improve
-
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-28 Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li, Xiaonan Chen
Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical
-
Hyperhomocysteinemia potentiates megakaryocyte differentiation and thrombopoiesis via GH-PI3K-Akt axis J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-27 Wenjing Lei, Zhuoliang Liu, Zhiyuan Su, Panpan Meng, Chun Zhou, Xiaomei Chen, Zheng Hu, An Xiao, Miaomiao Zhou, Liping Huang, Yiyue Zhang, Xianhui Qin, Junping Wang, Fengxin Zhu, Jing Nie
Hyperhomocysteinemia (HHcy) is closely associated with thrombotic diseases such as myocardial infarction and stroke. Enhanced platelet activation was observed in animals and humans with HHcy. However, the influence of HHcy on thrombopoiesis remains largely unknown. Here, we reported increased platelet count (PLT) in mice and zebrafish with HHcy. In hypertensive patients (n = 11,189), higher serum level
-
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-27 Antonio Tapia-Galisteo, Luis Álvarez-Vallina, Laura Sanz
Immune cell engagers are engineered antibodies with at least one arm binding a tumor-associated antigen and at least another one directed against an activating receptor in immune effector cells: CD3 for recruitment of T cells and CD16a for NK cells. The first T cell engager (the anti-CD19 blinatumomab) was approved by the FDA in 2014, but no other one hit the market until 2022. Now the field is gaining
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-27 Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu, John Mascarenhas
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. Patients with MF are at risk for reduced survival versus the general population and often experience burdensome signs and symptoms that reduce quality of life. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was initially approved by the
-
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-25 N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jiménez-Ubieto, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz, J. Martinez-Lopez
Correction : Journal of Hematology & Oncology (2023) 16:76 https://doi.org/10.1186/s13045-023-01474-w The original article [1] mistakenly truncated co-author, A. Jiménez-Ubieto’s name which has since been amended. Lopez-Muñoz N, et al. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma. J Hematol Oncol. 2023;16:76. Article PubMed PubMed Central Google Scholar Download
-
Metabolism, metabolites, and macrophages in cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-25 Mengyuan Li, Yuhan Yang, Liting Xiong, Ping Jiang, Junjie Wang, Chunxiao Li
Tumour-associated macrophages (TAMs) are crucial components of the tumour microenvironment and play a significant role in tumour development and drug resistance by creating an immunosuppressive microenvironment. Macrophages are essential components of both the innate and adaptive immune systems and contribute to pathogen resistance and the regulation of organism homeostasis. Macrophage function and
-
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-22 Maria-Luisa Schubert, Anita Schmitt, Angela Hückelhoven-Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp-Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas Kulozik, Joachim Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper
Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL). Thirteen patients were treated with escalating doses
-
Novel target and treatment agents for natural killer/T-cell lymphoma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-22 Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
The rapidly increasing use of high-throughput screening had produced a plethora of expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL), which in turn has revolutionized the treatment. Specifically, the use of asparaginase-containing regimens has led to substantial improvement in survival outcomes in NKTCL patients. Novel treatment strategies that are currently under
-
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-20 Jiawei Fan, Ye Yu, Lanzhen Yan, Yuncang Yuan, Bin Sun, Dong Yang, Nan Liu, Jing Guo, Jie Zhang, Xudong Zhao
The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells and tumor-associated macrophages and promote the development of cancers including pancreatic tumor. Targeting TAM receptors could be a promising therapeutic option. We designed a novel CAR based on the extracellular domain of growth arrest-specific protein 6 (GAS6), a natural ligand
-
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-19 N. Lopez-Muñoz, G. Hernández-Ibarburu, R. Alonso, J. M. Sanchez-Pina, R. Ayala, M. Calbacho, C. Cuellar, M. T. Cedena, A. Jimenez, R. Iñiguez, M. Pedrera, J. Cruz, L. Meloni, D. Pérez-Rey, P. Serrano, J. de la Cruz, J. Martinez-Lopez
Survival in multiple myeloma has improved significantly in recent years, especially in young patients. We reviewed the evolution of the survival of patients with MM in three groups based on age at MM diagnosis over three time periods between 1999 and 2020 at our 12 de Octubre Hospital institution (H12O). Then, to confirm our results, we used data from TriNetx, a global health research platform that
-
Clinical development of mRNA therapies against solid tumors J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-07-18 Dawei Wu, Lingfeng Hu, Xin Wang, Yue Yu, Shuo-Peng Jia, Hui-Yao Huang, Zi-Wei Li, Jin-Feng Ma, Hai-Bo Zhu, Yu Tang, Ning Li
The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove database, a total of 108 clinical trials from 1999 to 2021 were retrospectively analyzed. We have demonstrated